A New Domain Structure for the IMPACT‐III Health‐related Quality of life Tool for Pediatric Inflammatory Bowel Disease
- 2 July 2020
- journal article
- research article
- Published by Wiley in Journal of Pediatric Gastroenterology and Nutrition
- Vol. 71 (4) , 494-500
Abstract
Background: The IMPACT‐III measures health‐related quality of life (HRQOL) in pediatric patients with Inflammatory Bowel Disease (IBD). The original IMPACT domain structure was developed based on expert opinion and was not psychometrically validated. This study developed a new domain structure based on the current IMPACT version.Methods: Baseline data from 3 prospectively collected datasets of children and adolescents with IBD was used. Exploratory, then confirmatory factor analyses were carried out to develop a new domain structure. Internal consistency (Cronbach alpha) and construct validity with PROMIS measures (Pearson correlations, and Independent Mann‐Whitney U‐tests) were examined.Results: Data from the IBD Partners dataset alone (n = 374; 47% girls, mean age = 13.4 ± 2.5 years, median disease duration = 2.5 years, 75% were in remission, with a range of self‐reported disease activity) was used to validate the new 4‐domain IMPACT‐III model. The final domain structure was parsimonious, with factor loadings for individual items ranging from 0.39 to 0.80, and internal consistency for domains from 0.75 to 0.95. The new IMPACT‐III domains include: General well‐being, Social Functioning, Emotional functioning, and Body Image. IMPACT‐III total and domain scores were significantly lower (all P < 0.001) for participants with high (>50) versus low (T‐scores; conversely IMPACT‐III scores were higher for participants with higher peer‐relations PROMIS T‐scores.Conclusions: This valid and reliable IMPACT‐III domain structure should be used to capture pediatric self‐reported HRQOL, which will help to understand the management of IBD from the perspective of patients.Keywords
This publication has 32 references indexed in Scilit:
- Induction and Maintenance Therapy With Infliximab for Children With Moderate to Severe Ulcerative ColitisClinical Gastroenterology and Hepatology, 2012
- Short pediatric Crohnʼs disease activity index for quality improvement and observational researchInflammatory Bowel Diseases, 2011
- PROMIS Pediatric Pain Interference Scale: An Item Response Theory Analysis of the Pediatric Pain Item BankThe Journal of Pain, 2010
- An item response analysis of the pediatric PROMIS anxiety and depressive symptoms scalesQuality of Life Research, 2010
- Sampling plan and patient characteristics of the PROMIS pediatrics large-scale surveyQuality of Life Research, 2010
- Measuring Quality of Life in Pediatric Patients With Inflammatory Bowel Disease: Psychometric and Clinical CharacteristicsJournal of Pediatric Gastroenterology and Nutrition, 2008
- Induction and Maintenance Infliximab Therapy for the Treatment of Moderate-to-Severe Crohn’s Disease in ChildrenGastroenterology, 2007
- IMPACT‐III Is a Valid, Reliable and Responsive Measure of Health‐related Quality of Life in Pediatric Crohn's DiseaseJournal of Pediatric Gastroenterology and Nutrition, 2006
- Cutoff criteria for fit indexes in covariance structure analysis: Conventional criteria versus new alternativesStructural Equation Modeling: A Multidisciplinary Journal, 1999
- Measuring the impact of medical care on childrenJournal of Chronic Diseases, 1987